ArticleTranslational lung cancer research2022
Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer.
Andrea De Giglio et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.